Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00309946 · ClinicalTrials.gov registry record · Phase 2
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00309946: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00309946 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00309946, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
This phase II trial is studying how well cediranib maleate works in treating patients with malignant mesothelioma that cannot be removed by surgery. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor
Interventions
- DRUG cediranib maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2005-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00309946
The ClinicalTrials.gov registry entry for NCT00309946 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cediranib maleate is the first listed.
NCT00309946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00309946 about?
NCT00309946 is a clinical study titled "Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery". This phase II trial is studying how well cediranib maleate works in treating patients with malignant mesothelioma that cannot be removed by surgery. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor
What is the current status of trial NCT00309946?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2005-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00309946?
The interventions under investigation include: cediranib maleate (DRUG).
Who is sponsoring clinical trial NCT00309946?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.